Skip to content

Author

R. Smith

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Age and CMV are not associated with clinical or immunological response to immune checkpoint blockade

Ageing and cytomegalovirus (CMV) infection drive major alterations to T-cell immunity. Age is also associated with an increased risk of cancers including melanoma, which is treated with T-cell modifying immune checkpoint blockade (ICB). However, the extent to which age, CMV, and treatment-induced immune changes interac...

J. M. Edwards, S. Senthi, R. Smith et al. · 0 citations
Open access Jul 2026

Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

A phase 1/2 trial of an off-the-shelf stem cell-derived dopaminergic progenitor therapy demonstrated a favorable 12-month safety profile, with no graft-related adverse events, dyskinesias or tumor formation, although risks were associated with the immunosuppression regimen.

G. Paul, H. Bjartmarz, A. Kirkeby et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.